Publications by authors named "N G Dahl"

Article Synopsis
  • Over 50% of individuals with autosomal dominant polycystic kidney disease (ADPKD) will experience kidney failure, making it the 4th leading cause of end-stage kidney disease.
  • ADPKD is a systemic disorder impacting not just the kidneys, but also the liver, heart, and other organs, with some patients facing severe issues like liver enlargement or aneurysm ruptures.
  • Recent advances in genetics, prognosis, and treatment strategies have enabled personalized care that can alter the disease's progression, with the review emphasizing diagnosis, kidney failure risk assessment, treatment options, blood pressure control, and genetic testing.
View Article and Find Full Text PDF

MYC-driven medulloblastoma (MB) is a highly aggressive cancer type with poor prognosis and limited treatment options. Through CRISPR-Cas9 screening of MB cell lines, we identified the Mediator-associated kinase CDK8 as a critical regulator of MYC-driven MB. Loss of CDK8 substantially reduces MYC expression, induces pronounced transcriptional changes, suppresses monosome assembly, and decreases ribosome biogenesis and protein synthesis, consequently inhibiting MB growth.

View Article and Find Full Text PDF

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disorder and the fourth leading cause of kidney failure (KF) in adults. Characterized by a reduction in glomerular filtration rate (GFR) and increased kidney size, ADPKD exhibits significant variability in progression, highlighting the urgent need for reliable and predictive biomarkers to optimize management and treatment approaches. This review explores the roles of diverse biomarkers-including clinical, genetic, molecular, and imaging biomarkers-in evaluating disease progression and customizing treatments for ADPKD.

View Article and Find Full Text PDF
Article Synopsis
  • Time sensitivity is crucial for treating acute seizures, and reducing delays in medication preparation can enhance treatment effectiveness.
  • This study analyzed the safety and tolerability of IV undiluted levetiracetam in pediatric patients, focusing on adverse drug events related to concentration.
  • Results showed no concentration-related adverse events in 60 administrations among 52 patients, suggesting that IV undiluted levetiracetam is safe and tolerable for children, though further prospective studies are needed.
View Article and Find Full Text PDF

A key step in developing engineered B cells for therapeutic purposes is evaluation in immunocompetent, large-animal models. Therefore, we developed methods to purify, expand, and differentiate non-human primate (NHP; rhesus macaque) B cells. After 7 days in culture, B cells expanded 10-fold, differentiated into a plasma cell phenotype (CD38, CD138), and secreted immunoglobulin G.

View Article and Find Full Text PDF